Eric Eisenstadt and Marvin Frazier will remain vice presidents for research of TIGR and TCAG, respectively, while Yu-Hui Rogers will continue to direct the Joint Technology Center with support from a senior management team.
James Glover, Charles Slacik, Ronni Sherman, Craig Venter, Claire Fraser-Liggett, Robert Strausberg, Eric Eisenstadt, Marvin Frazier, Yu-Hui Rogers
Anadys Pharmaceuticals has named James Glover chief financial officer and senior vice president of operations, effective immediately. Glover comes to Anadys from Beckman Coulter, where he was chief financial officer.
As reported by BioCommerce Week last week, Charles Slacik recently left his post as CFO of Watson Pharmaceuticals to join Beckman Coulter as CFO. According to an 8-K filing with the US Securities and Exchange Commission last week, Slacik will receive an initial base salary of $475,000 and will be granted 60,000 shares of Beckman Coulter stock options equal to the closing price of the firm’s stock on the first Monday of the month subsequent to his start date.
Ronni Sherman has resigned from Stratagene as executive vice president and general counsel as of Oct. 13, the company said last week in an 8-K filing with the US Securities and Exchange Commission. However, she will remain as a paid hourly consultant for an additional period of one year at rates of $250-$350 per hour depending on the services rendered.
Sherman will also receive a lump sum payment of approximately $224,000 and will be entitled to receive an additional $40,000 in quarterly $10,000 installments over the next 12 months.
“In addition, she will be entitled to receive a minimum retainer for her consulting services of $10,000 per three-month period during each of the next four three-month periods,” according to Stratagene’s filing.
Half of Sherman’s hourly consulting service billings will be credited against such retainer amounts. Her medical insurance benefits will also be continued at Stratagene’s expense for a period of 18 months.
Sherman had been employed by Stratagene for more than 18 years.
Craig Venter became president and CEO of a newly expanded J. Craig Venter Institute after it absorbed the Institute for Genomic Research and the J. Craig Venter Science Foundation.
Claire Fraser-Liggett will remain president of TIGR and Robert Strausberg, group leader of human genome medicine at the Venter Institute, will become president of the Center for the Advancement of Genomics, which was renamed from JCVI. TIGR and TCAG will be divisions of the Venter Institute.